JP2017523206A - ブルトン型チロシンキナーゼ阻害剤の新規製剤 - Google Patents

ブルトン型チロシンキナーゼ阻害剤の新規製剤 Download PDF

Info

Publication number
JP2017523206A
JP2017523206A JP2017505606A JP2017505606A JP2017523206A JP 2017523206 A JP2017523206 A JP 2017523206A JP 2017505606 A JP2017505606 A JP 2017505606A JP 2017505606 A JP2017505606 A JP 2017505606A JP 2017523206 A JP2017523206 A JP 2017523206A
Authority
JP
Japan
Prior art keywords
formulation
ibrutinib
compound
polymer
solid dispersion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017505606A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523206A5 (enExample
Inventor
シュ，カサンドラ
アトゥルーリ，ハリシャ
キュール，ロバート
シュウェ−チョ タイ，パール
シュウェ−チョ タイ，パール
ミッチェル ミンキス，ライアン
ミッチェル ミンキス，ライアン
フランシス フルバット，ジェイムス
フランシス フルバット，ジェイムス
ジェイコブ マクベイ，アレキサンダー
ジェイコブ マクベイ，アレキサンダー
チョン，チン−ワ
Original Assignee
ファーマサイクリックス エルエルシー
ファーマサイクリックス エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーマサイクリックス エルエルシー, ファーマサイクリックス エルエルシー filed Critical ファーマサイクリックス エルエルシー
Publication of JP2017523206A publication Critical patent/JP2017523206A/ja
Publication of JP2017523206A5 publication Critical patent/JP2017523206A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017505606A 2014-08-07 2015-08-07 ブルトン型チロシンキナーゼ阻害剤の新規製剤 Pending JP2017523206A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462034353P 2014-08-07 2014-08-07
US62/034,353 2014-08-07
PCT/US2015/044258 WO2016022942A1 (en) 2014-08-07 2015-08-07 Novel formulations of a bruton's tyrosine kinase inhibitor

Publications (2)

Publication Number Publication Date
JP2017523206A true JP2017523206A (ja) 2017-08-17
JP2017523206A5 JP2017523206A5 (enExample) 2018-09-20

Family

ID=55264642

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017505606A Pending JP2017523206A (ja) 2014-08-07 2015-08-07 ブルトン型チロシンキナーゼ阻害剤の新規製剤

Country Status (13)

Country Link
US (4) US9545407B2 (enExample)
EP (1) EP3193877A4 (enExample)
JP (1) JP2017523206A (enExample)
KR (1) KR20170033358A (enExample)
CN (1) CN106573002A (enExample)
AU (1) AU2015300798A1 (enExample)
BR (1) BR112017002231A2 (enExample)
CA (1) CA2955747A1 (enExample)
IL (1) IL250085A0 (enExample)
MX (1) MX2017001671A (enExample)
RU (1) RU2017106795A (enExample)
SG (1) SG11201700849XA (enExample)
WO (1) WO2016022942A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021532159A (ja) * 2018-07-31 2021-11-25 ロクソ オンコロジー, インコーポレイテッドLoxo Oncology, Inc. （ｓ）−５−アミノ−３−（４−（（５−フルオロ−２−メトキシベンズアミド）メチル）フェニル）−１−（１，１，１−トリフルオロプロパン−２−イル）−１ｈ−ピラゾール−４−カルボキサミドの噴霧乾燥分散体および製剤
JP2022525797A (ja) * 2019-04-11 2022-05-19 ゴールドフィンチ バイオ，インク． ピリダジノンｔｒｐｃ５阻害剤の噴霧乾燥された製剤
JP2022533368A (ja) * 2019-05-17 2022-07-22 セルジーン シーエーアール エルエルシー Ｍｋ２媒介性障害の治療方法

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ753024A (en) 2010-06-03 2020-08-28 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
CN104736178A (zh) 2012-06-04 2015-06-24 药品循环公司 布鲁顿酪氨酸激酶抑制剂的晶形
CA2879570A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
SG11201700849XA (en) * 2014-08-07 2017-03-30 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
CN113546054A (zh) * 2015-04-06 2021-10-26 詹森药业有限公司 包含依鲁替尼的组合物
MX2018008771A (es) * 2016-01-19 2018-11-09 Janssen Pharmaceutica Nv Formulaciones/composiciones que comprenden un inhibidor de btk.
CA3061185A1 (en) * 2017-04-24 2018-11-01 Samus Therapeutics, Inc. Hsp90 inhibitor oral formulations and related methods
CN107014943B (zh) * 2017-06-07 2018-08-21 福建省微生物研究所 一种依鲁替尼对映异构体的检测方法
ES2909583T3 (es) * 2017-06-30 2022-05-09 Acrotech Biopharma Llc Nuevas formulaciones orales de belinostat
KR102697985B1 (ko) * 2017-07-04 2024-08-23 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 약학 조성물 및 이를 제조하기 위한 방법
SG11202001129VA (en) * 2017-08-11 2020-03-30 Merck Patent Gmbh Pharmaceutical preparation comprising 3-fluoro-4-[7-methoxy-3-methyl-8-(1-methyl-1 h-pyrazol-4-yl)-2-oxo-2,3-dihydro-imidazo[4,5-c]quinolin-1 -yl]-benzonitrile
WO2019058386A1 (en) 2017-09-19 2019-03-28 Cipla Limited COMPOSITIONS COMPRISING IBRUTINIB AND AN ALKALOID HAVING IMPROVED BIOAVAILABILITY
WO2019070698A1 (en) 2017-10-02 2019-04-11 Johnson Matthey Public Limited Company Novel forms of ibrutinib
CN111212644B (zh) * 2017-11-10 2021-01-15 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的无定型固体分散体
CZ2017787A3 (cs) * 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
US11576917B2 (en) 2018-01-20 2023-02-14 Natco Pharma Limited Pharmaceutical compositions comprising Ibrutinib
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
KR102867888B1 (ko) 2018-01-31 2025-10-13 데시페라 파마슈티칼스, 엘엘씨 비만 세포증의 치료를 위한 병용 요법
WO2019195827A1 (en) 2018-04-06 2019-10-10 Johnson Matthey Public Limited Company Novel form of ibrutinib
SG11202010642TA (en) 2018-05-03 2020-11-27 Juno Therapeutics Inc Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
JP7695078B2 (ja) 2018-06-15 2025-06-18 ヤンセン ファーマシューティカ エヌ．ベー． イブルチニブを含む配合物／組成物
WO2020185812A1 (en) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
AU2020353381A1 (en) * 2019-09-23 2022-04-07 Bionomics Limited Therapeutic formulations and uses thereof
KR20250057151A (ko) 2019-12-30 2025-04-28 데시페라 파마슈티칼스, 엘엘씨 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의조성물
IL293866A (en) 2019-12-30 2022-08-01 Deciphera Pharmaceuticals Llc Compositions of amorphous kinase inhibitors and methods of using them
CA3181361A1 (en) * 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN111617028A (zh) * 2020-07-14 2020-09-04 扬子江药业集团江苏紫龙药业有限公司 一种含伊布替尼的口服制剂及制备方法
CN114681424A (zh) * 2020-12-31 2022-07-01 鲁南制药集团股份有限公司 一种伊布替尼胶囊及其制备方法
US20240024248A1 (en) * 2021-01-21 2024-01-25 Xspray Pharma Ab Fast dissolving pharmaceutical compositions
WO2022157308A1 (en) * 2021-01-21 2022-07-28 Xspray Pharma Ab (Publ) Fast dissolving pharmaceutical compositions of dasatinib
EP4301345A4 (en) * 2021-03-03 2025-01-08 Oakwood Laboratories, Llc Microsphere formulations comprising btk inhibitors and methods for making and using the same
CN113509443B (zh) * 2021-07-14 2023-04-11 药源生物科技（启东）有限公司 一种含soluplus的固分体及其制备方法
WO2023104808A1 (en) * 2021-12-10 2023-06-15 Synthon B.V. Pharmaceutical composition comprising ibrutinib
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
CN115054603A (zh) * 2022-06-20 2022-09-16 上海宣泰医药科技股份有限公司 依鲁替尼药物组合物及其制备方法和药物制剂

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000229887A (ja) * 1999-02-10 2000-08-22 Pfizer Prod Inc 医薬用固体分散物
JP2001527044A (ja) * 1997-12-31 2001-12-25 チョンワエ ファーマ コーポレーション イトラコナゾール（ｉｔｒａｃｏｎａｚｏｌｅ）経口用製剤及びその製造方法
JP2004521918A (ja) * 2001-02-27 2004-07-22 アストラゼネカ アクチボラグ 医薬製剤
JP2007504103A (ja) * 2003-08-29 2007-03-01 ライフサイクル ファーマ アクティーゼルスカブ タクロリムスを含む固体分散体
JP2009530415A (ja) * 2006-03-20 2009-08-27 バーテックス ファーマシューティカルズ インコーポレイテッド 医薬組成物
US20130338172A1 (en) * 2012-06-04 2013-12-19 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3303707A1 (de) 1983-02-04 1984-08-09 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur spaltung von organosiloxanen und dessen produkte und anwendungen
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
JPH01167840A (ja) 1987-12-24 1989-07-03 Konica Corp 新規な写真用シアンカプラー
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
TR199902301T2 (xx) 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
DE69918089T2 (de) 1998-04-17 2005-07-14 Parker Hughes Institute, St. Paul Btk inhibitoren und verfahren zur identifizierung und verwendung
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US6998233B2 (en) 1998-06-26 2006-02-14 Sunesis Pharmaceuticals, Inc. Methods for ligand discovery
US20050287596A9 (en) 1998-06-26 2005-12-29 Braisted Andrew C Novel ligands and libraries of ligands
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
UA74141C2 (uk) 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6306897B1 (en) 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
EP1212327B8 (en) 1999-09-17 2004-02-25 Abbott GmbH & Co. KG Pyrazolopyrimidines as therapeutic agents
ATE277044T1 (de) 1999-10-06 2004-10-15 Boehringer Ingelheim Pharma Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
JP2003516351A (ja) 1999-11-30 2003-05-13 パーカー ヒューズ インスティテュート コラーゲン誘導血小板凝集阻害剤
AU2439701A (en) 1999-12-17 2001-06-25 Ariad Pharmaceuticals, Inc. Novel heterocycles
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
GB0108903D0 (en) 2000-10-05 2001-05-30 Aventis Pharm Prod Inc Novel crystalline forms of a factor Xa inhibitor
EP1373554A2 (en) 2000-10-23 2004-01-02 Bristol-Myers Squibb Company Modulators of bruton's tyronsine kinase, their identification and use
CA2436570A1 (en) 2000-12-06 2002-06-13 Pharmacia Corporation Rapidly dispersing pharmaceutical composition comprising effervescent agents
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US8306897B2 (en) 2001-05-04 2012-11-06 Stockshield, Inc. Method and system for insuring against investment loss
WO2003000187A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
WO2003014732A1 (en) 2001-08-10 2003-02-20 Symyx Technologies, Inc. Apparatuses and methods for creating and testing pre-formulations and systems for same
CA2810339A1 (en) 2001-08-10 2003-02-20 Novartis Ag Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
WO2003016338A1 (en) 2001-08-15 2003-02-27 Parker Hughes Institute Crystal structure of the btk kinase domain
JP4391237B2 (ja) 2001-11-21 2009-12-24 サネシス ファーマシューティカルズ， インコーポレイテッド リガンド発見のための方法
US20050084905A1 (en) 2002-03-21 2005-04-21 Prescott John C. Identification of kinase inhibitors
GB2388594A (en) 2002-05-16 2003-11-19 Bayer Ag Imidazo-triazine PDE 4 inhibitors
CA2494942A1 (en) 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
US7687506B2 (en) 2003-04-11 2010-03-30 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
WO2004100868A2 (en) 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
US8131475B2 (en) 2003-09-03 2012-03-06 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
ATE525377T1 (de) 2003-10-15 2011-10-15 Osi Pharm Inc Imidazoä1,5-aüpyrazine als inhibitoren von tyrosinkinase
US20070196395A1 (en) 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
US20050153990A1 (en) 2003-12-22 2005-07-14 Watkins William J. Phosphonate substituted kinase inhibitors
US20070281907A1 (en) 2003-12-22 2007-12-06 Watkins William J Kinase Inhibitor Phosphonate Conjugates
CN1934113B (zh) 2004-01-26 2011-11-09 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的组合物
CA2553724A1 (en) 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
ITMI20041314A1 (it) 2004-06-30 2004-09-30 Nuvera Fuel Cells Europ Srl Dispositivo di raffreddamento per celle a combustibili a membrana
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
EP1794137A4 (en) 2004-09-27 2009-12-02 Kosan Biosciences Inc SPECIFIC KINASE INHIBITORS
EA200700757A1 (ru) 2004-09-28 2007-10-26 Янссен Фармацевтика Н.В. Замещённые дипиперидиновые антагонисты ccr2
SG159549A1 (en) 2004-11-10 2010-03-30 Cgi Pharmaceuticals Inc Imidazo[1,2-a] pyrazin-8-ylamines useful as modulators of kinase activity
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds
BRPI0608840B8 (pt) 2005-03-07 2021-05-25 Batyer Healthcare Ag composição farmacêutica compreendendo uma difenil uréia substituída por ômega-carboxiarila, e seu processo de preparação
AU2006223409B2 (en) 2005-03-10 2011-07-21 Gilead Connecticut, Inc. Certain substituted amides, method of making, and method of use thereof
KR20080025039A (ko) 2005-05-13 2008-03-19 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물 및 조성물
PL1893612T3 (pl) 2005-06-22 2012-01-31 Plexxikon Inc Pochodne pirolo-[2,3-b]pirydyny jako inhibitory kinazy białkowej
US20070065449A1 (en) 2005-09-16 2007-03-22 Claire Verschraegen Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
EP1957491A2 (en) 2005-11-12 2008-08-20 Boehringer Ingelheim International GmbH Pyrrolo (2,3-b) pyridine derivatives useful as tec kinase inhibitors
MX2008008642A (es) 2006-01-13 2008-09-12 Pharmacyclics Inc Inhibidores de las tirosina cinasas y usos de los mismos.
ES2420834T3 (es) 2006-01-30 2013-08-27 The Scripps Research Institute Métodos de detección de células tumorales circulantes y métodos de diagnóstico del cáncer en un sujeto mamífero
JP2009532507A (ja) 2006-04-04 2009-09-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｐｉ３キナーゼアンタゴニスト
CA2651732C (en) 2006-05-18 2014-10-14 Mannkind Corporation Intracellular kinase inhibitors
DE102006026583A1 (de) 2006-06-07 2007-12-13 Bayer Healthcare Aktiengesellschaft Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung
SI2529622T1 (en) 2006-09-22 2018-06-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2008054827A2 (en) 2006-11-03 2008-05-08 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
NL2000640C2 (nl) 2007-03-05 2008-09-08 Stichting Wetsus Ct Of Excelle Werkwijze en systeem voor het zuiveren van een vloeistof.
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US20120065201A1 (en) 2007-03-28 2012-03-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
SG10201508035TA (en) 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
US20090010911A1 (en) 2007-04-06 2009-01-08 Iowa State University Research Foundation, Inc. Methods and compositions for affecting cyclophilin a regulation of kinases in modulating cellular activities
TWI552752B (zh) 2007-10-19 2016-10-11 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
EP2426109B1 (en) 2007-10-23 2013-12-18 F. Hoffmann-La Roche AG Novel kinase inhibitors
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
US20150152115A1 (en) 2007-12-27 2015-06-04 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
CA3066426A1 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
MX2010011314A (es) 2008-04-14 2010-11-12 Ardea Biosciences Inc Composiciones y metodos de preparacion y uso de las mismas.
EP2123626A1 (en) 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
TWI546290B (zh) 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
WO2010009342A2 (en) 2008-07-16 2010-01-21 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
MX2011001005A (es) 2008-07-29 2011-09-01 Frontier Scient Inc Uso de derivados de tetraquis (n-alquilpiridinio)-porfirina para eliminacion de microbios o prevencion del crecimiento.
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
WO2010068806A1 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
RU2012114902A (ru) 2009-09-16 2013-10-27 Авила Терапьютикс, Инк. Конъюгаты и ингибиторы протеинкиназы
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
EP3112368B1 (en) 2010-05-31 2020-02-12 Ono Pharmaceutical Co., Ltd. Purinone derivative as btk kinase inhibitor
NZ753024A (en) 2010-06-03 2020-08-28 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
RU2585177C2 (ru) 2010-06-23 2016-05-27 Ханми Сайенс Ко., Лтд. Новые конденсированные пиримидиновые производные для ингибирования тирозинкиназной активности
EP2603081B1 (en) 2010-08-10 2016-10-05 Celgene Avilomics Research, Inc. Besylate salt of a btk inhibitor
US8541391B2 (en) 2010-10-28 2013-09-24 Viropharma Incorporated Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole
US8501484B2 (en) 2011-03-14 2013-08-06 Los Alamos National Security, Llc Preparation of cerium halide solvate complexes
MX2011004759A (es) 2011-05-04 2012-11-21 Senosiain S A De C V Lab Nuevas formas solidas de antibioticos.
BR112013028846B1 (pt) 2011-05-17 2021-12-07 Principia Biopharma Inc Composto ou sal farmaceuticamente aceitável do mesmo, respectivos usos, processo de preparação, intermediários e composição farmacêutica
US20140288037A1 (en) 2011-07-18 2014-09-25 Tokai Pharmaceuticals, Inc. Novel compositions and methods for treating prostate cancer
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
EP3181128B1 (en) 2012-01-13 2023-03-08 XSpray Pharma AB (publ) Nilotinib pharmaceuticalcomposition
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
JP5514256B2 (ja) 2012-05-18 2014-06-04 株式会社東芝 磁気記憶素子及びその製造方法
WO2013191965A1 (en) 2012-06-18 2013-12-27 Principia Biopharma Inc. Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases
US20150140085A1 (en) 2012-06-29 2015-05-21 Principia Biopharma Inc. Formulations comprising ibrutinib
CA2879570A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
CN103121999A (zh) 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
KR20150084923A (ko) 2012-11-15 2015-07-22 파마시클릭스, 인코포레이티드 키나제 억제제로서의 피롤로피리미딘 화합물
WO2014179528A2 (en) 2013-05-01 2014-11-06 Brown Dennis M Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
AU2014273946B2 (en) 2013-05-30 2020-03-12 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
AR097204A1 (es) 2013-08-02 2016-02-24 Pharmacyclics Inc Métodos de tratamiento de tumores sólidos
WO2015034478A1 (en) 2013-09-04 2015-03-12 Halliburton Energy Services, Inc. Scale-inhibiting cocrystals for treatment of a subterranean formation
AU2014318614B2 (en) 2013-09-12 2021-01-07 Dana-Farber Cancer Institute Inc. Methods for evaluating and treating Waldenstrom's macroglobulinemia
TWI617309B (zh) 2013-10-25 2018-03-11 製藥公司 使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法
WO2015071432A1 (en) 2013-11-14 2015-05-21 Sandoz Ag Pharmaceutical compositions of ibrutinib
CN103694241A (zh) 2013-11-27 2014-04-02 苏州晶云药物科技有限公司 Pci-32765的新晶型a及其制备方法
CA2933900A1 (en) 2013-12-20 2015-06-25 Georgia Tech Research Corporation Formulations and methods for targeted ocular delivery of therapeutic agents
CN106008516A (zh) 2014-01-29 2016-10-12 苏州晶云药物科技有限公司 依鲁替尼的新晶型及其制备方法
CA2938244A1 (en) 2014-02-07 2015-08-13 Auspex Pharamaceuticals, Inc. Novel pharmaceutical formulations
US20150231077A1 (en) 2014-02-17 2015-08-20 The Cleveland Clinic Foundation Amine passivated nanoparticles for cancer treatment and imaging
WO2015127261A1 (en) 2014-02-21 2015-08-27 Pharmacyclics, Inc. Biomarkers for predicting response of dlbcl to treatment with ibrutinib
US20150267752A1 (en) 2014-03-19 2015-09-24 Roller Bearing Company Of America, Inc. Bearing outer race having a radially inwardly biased seal
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
CA2941087A1 (en) 2014-03-27 2015-10-01 Perrigo Api Ltd Ibrutinib solid forms and production process therefor
CN105085529A (zh) 2014-05-15 2015-11-25 广东东阳光药业有限公司 依鲁替尼新晶型及其制备方法
US9127069B1 (en) 2014-06-11 2015-09-08 Antecip Bioventures LLC Compositions comprising rank/rankl antagonists and related compounds for treating pain
US20150110871A1 (en) 2014-06-02 2015-04-23 David Wong Gastric retentive tablet compositions
WO2016007617A2 (en) 2014-07-09 2016-01-14 Novotec Consulting, Llc. Pharmaceutical compounding kit
PT107846B (pt) 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
WO2016020697A1 (en) 2014-08-06 2016-02-11 Cipla Limited Pharmaceutical compositions of polymeric nanoparticles
SG11201700849XA (en) * 2014-08-07 2017-03-30 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
EP3180343A1 (en) 2014-08-14 2017-06-21 Assia Chemical Industries Ltd. Solid state forms of ibrutinib
EP3201197B1 (en) 2014-10-01 2019-03-27 ratiopharm GmbH Acid addition salt of ibrutinib
CN104523695A (zh) 2014-11-12 2015-04-22 广东东阳光药业有限公司 一种治疗过度增生性疾病的药物组合物
CN105640961A (zh) 2014-11-18 2016-06-08 山东瑞禾医药科技有限公司 一种含依鲁替尼的药物组合物
WO2016079216A1 (en) 2014-11-20 2016-05-26 Sandoz Ag Physical forms of ibrutinib, a bruton's kinase inhibitor
US20150224060A1 (en) 2015-01-03 2015-08-13 David Wong Gastric retentive tablet compositions
CZ201584A3 (cs) 2015-02-09 2016-08-17 Zentiva, K.S. Sůl Ibrutinib sulfátu
US20180051026A1 (en) 2015-03-03 2018-02-22 Dr. Reddy's Laboratories Limited Polymorphs of ibrutinib
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
US10377758B2 (en) 2015-04-02 2019-08-13 Ratiopharm Gmbh Co-crystals of ibrutinib with carboxylic acids
CN113546054A (zh) 2015-04-06 2021-10-26 詹森药业有限公司 包含依鲁替尼的组合物
CN105294696A (zh) 2015-11-19 2016-02-03 上海创诺医药集团有限公司 依鲁替尼新晶型及其制备方法
CN105440040B (zh) 2015-12-23 2018-03-13 浙江京新药业股份有限公司 依鲁替尼的纯化方法
CN105646499A (zh) 2016-03-01 2016-06-08 孙霖 依鲁替尼晶型g及制备方法
CN105646484A (zh) 2016-03-01 2016-06-08 孙霖 晶型b及制备方法
CN105646498A (zh) 2016-03-01 2016-06-08 孙霖 依鲁替尼晶型f及制备方法
CN106619643A (zh) 2016-11-11 2017-05-10 上海雅本化学有限公司 一种含依鲁替尼的药物组合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001527044A (ja) * 1997-12-31 2001-12-25 チョンワエ ファーマ コーポレーション イトラコナゾール（ｉｔｒａｃｏｎａｚｏｌｅ）経口用製剤及びその製造方法
JP2000229887A (ja) * 1999-02-10 2000-08-22 Pfizer Prod Inc 医薬用固体分散物
JP2004521918A (ja) * 2001-02-27 2004-07-22 アストラゼネカ アクチボラグ 医薬製剤
JP2007504103A (ja) * 2003-08-29 2007-03-01 ライフサイクル ファーマ アクティーゼルスカブ タクロリムスを含む固体分散体
JP2009530415A (ja) * 2006-03-20 2009-08-27 バーテックス ファーマシューティカルズ インコーポレイテッド 医薬組成物
US20130338172A1 (en) * 2012-06-04 2013-12-19 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021532159A (ja) * 2018-07-31 2021-11-25 ロクソ オンコロジー, インコーポレイテッドLoxo Oncology, Inc. （ｓ）−５−アミノ−３−（４−（（５−フルオロ−２−メトキシベンズアミド）メチル）フェニル）−１−（１，１，１−トリフルオロプロパン−２−イル）−１ｈ−ピラゾール−４−カルボキサミドの噴霧乾燥分散体および製剤
JP7286755B2 (ja) 2018-07-31 2023-06-05 ロクソ オンコロジー， インコーポレイテッド （ｓ）－５－アミノ－３－（４－（（５－フルオロ－２－メトキシベンズアミド）メチル）フェニル）－１－（１，１，１－トリフルオロプロパン－２－イル）－１ｈ－ピラゾール－４－カルボキサミドの噴霧乾燥分散体および製剤
JP2022525797A (ja) * 2019-04-11 2022-05-19 ゴールドフィンチ バイオ，インク． ピリダジノンｔｒｐｃ５阻害剤の噴霧乾燥された製剤
JP7607577B2 (ja) 2019-04-11 2024-12-27 ゴールドフィンチ バイオ，インク． ピリダジノンｔｒｐｃ５阻害剤の噴霧乾燥された製剤
JP2022533368A (ja) * 2019-05-17 2022-07-22 セルジーン シーエーアール エルエルシー Ｍｋ２媒介性障害の治療方法

Also Published As

Publication number Publication date
BR112017002231A2 (pt) 2018-07-17
AU2015300798A1 (en) 2017-02-02
CA2955747A1 (en) 2016-02-11
CN106573002A (zh) 2017-04-19
RU2017106795A3 (enExample) 2019-04-12
RU2017106795A (ru) 2018-09-07
US20170079981A1 (en) 2017-03-23
EP3193877A1 (en) 2017-07-26
IL250085A0 (en) 2017-03-30
WO2016022942A1 (en) 2016-02-11
KR20170033358A (ko) 2017-03-24
US20190282578A1 (en) 2019-09-19
SG11201700849XA (en) 2017-03-30
US20180028537A1 (en) 2018-02-01
US20160038496A1 (en) 2016-02-11
US9545407B2 (en) 2017-01-17
MX2017001671A (es) 2017-07-04
EP3193877A4 (en) 2018-04-04

Similar Documents

Publication Publication Date Title
US20250228783A1 (en) Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
US9545407B2 (en) Formulations of a bruton's tyrosine kinase inhibitor
JP2025186225A (ja) ブルトン型チロシンキナーゼ阻害剤の結晶形態
US20220106317A1 (en) Solvated forms of a bruton's tyrosine kinase inhibitor
KR20240087693A (ko) 암 치료를 위한 비가역적 메닌-mll 억제제인 n-[4-[4-(4-모르폴리닐)-7h-피롤로[2,3-d]피리미딘-6-일]페닐]-4-[[3(r)-[(1-옥소-2-프로펜-1-일)아미노]-1-피페리디닐]메틸]-2-피리딘카르복스아미드의 결정질 형태
JP2018509458A (ja) ブルトン型チロシンキナーゼ阻害剤の共結晶

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200629